Flat Q1 Revenues Reported by Epigenomics

During the quarter, the German molecular diagnostics firm met with FDA officials about a possible submission for its Epi proColon 2.0 test, and based on the meeting Epigenomics plans on an application for regulatory approval by the end of the year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories